| Original language | English (US) |
|---|---|
| Pages (from-to) | 3523 |
| Number of pages | 1 |
| Journal | International Journal of Cancer |
| Volume | 146 |
| Issue number | 12 |
| DOIs | |
| State | Published - Jun 15 2020 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Reply to comments on : Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption. / Podoltsev, Nikolai A.; Wang, Xiaoyi; Wang, Rong; Hofmann, Jonathan N.; Liao, Linda M.; Zeidan, Amer M.; Mesa, Ruben; Ma, Xiaomei.
In: International Journal of Cancer, Vol. 146, No. 12, 15.06.2020, p. 3523.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply to comments on
T2 - Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption
AU - Podoltsev, Nikolai A.
AU - Wang, Xiaoyi
AU - Wang, Rong
AU - Hofmann, Jonathan N.
AU - Liao, Linda M.
AU - Zeidan, Amer M.
AU - Mesa, Ruben
AU - Ma, Xiaomei
N1 - Funding Information: N.A.P. received research funding (institutional) from Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Astex Pharmaceuticals, CTI Biopharma, Celgene, Genentech, AI Therapeutics, Samus Therapeutics, Arog Pharmaceuticals and Kartos Therapeutics. N.A.P. had a consultancy with and received honoraria from Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene, Bristol‐Myers Squib and CTI biopharma. A.M.Z. received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer‐Ingelheim, Trovagene, Incyte, Takeda, Novartis, Aprea and ADC Therapeutics. A.M.Z had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer‐Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Trovagene, Takeda, Ionis and Epizyme. A.M.Z received travel support for meetings from Pfizer, Novartis, Celgene and Trovagene. RM had a consultancy with Novartis, Sierra Oncology, La Jolla and Pharma. R.M. received research funding from Celgene, Incyte, Abbvie, Samus, Genotech, Promedior and CTI.
PY - 2020/6/15
Y1 - 2020/6/15
UR - http://www.scopus.com/inward/record.url?scp=85082512786&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082512786&partnerID=8YFLogxK
U2 - 10.1002/ijc.32974
DO - 10.1002/ijc.32974
M3 - Letter
C2 - 32167580
AN - SCOPUS:85082512786
VL - 146
SP - 3523
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 12
ER -